Surgery is the standard treatment for nonmetastatic renal cell carcinoma. Despite curative intent, patients with a high risk of relapse have a 5-year metastasis-free survival rate of only 30% and prevention of recurrence is an unmet need. In a Phase III trial (JAVELIN Renal 101), progression-free survival of axitinib + avelumab was superior to sunitinib with a favorable objective response rate and no added toxicity profiles as known for axitinib or avelumab single agent. NEOAVAX is designed as open label, single arm, Phase II trial with a Simon's two-stage design evaluating neoadjuvant axitinib + avelumab followed by complete surgical resection in 40 patients with high-risk nonmetastatic clear-cell renal cell carcinoma. Primary end point is remission of the primary tumor (RECIST 1.1; Response Evaluation Criteria In Solid Tumors) following neoadjuvant therapy. Secondary end points include disease-free survival, overall survival, rate of metastasis and local recurrence, safety, and tolerability. Exploratory end points include investigation of effects on neoangiogenesis, immune infiltrates and myeloid-derived suppressor cell components to support a rationale for the combined use of axitinib and avelumab (NCT03341845).
Future oncology (London, England). 2019 Apr 26 [Epub ahead of print]
Axel Bex, Johan V van Thienen, Mariette Schrier, Niels Graafland, Teele Kuusk, Kees Hendricksen, Brunolf Lagerveld, Patricia Zondervan, Jeroen A van Moorselaar, Christian Blank, Sofie Wilgenbos, John Haanen
Department of Urology, Netherlands Cancer Institute, Amsterdam, The Netherlands., Department of Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands., Department of Urology, Onze Lieve Vrouwe Gasthuis, Amsterdam, The Netherlands., Department of Urology, Amsterdam University Medical Center, Amsterdam, The Netherlands.